These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24767765)

  • 1. Impact of high-dose statin pre-treatment and contrast-induced acute kidney injury on follow-up events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Patti G; Leoncini M; Toso A; Maioli M; Grieco D; Colonna G; Bellandi F; Di Sciascio G
    Int J Cardiol; 2014 Jun; 174(2):440-1. PubMed ID: 24767765
    [No Abstract]   [Full Text] [Related]  

  • 2. Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study.
    Leoncini M; Toso A; Maioli M; Tropeano F; Badia T; Villani S; Bellandi F
    Am Heart J; 2014 Nov; 168(5):792-7. PubMed ID: 25440809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of short-term high versus low doses of atorvastatin preventing contrast-induced acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention.
    Wu H; Li D; Fang M; Han H; Wang H
    J Clin Pharmacol; 2015 Feb; 55(2):123-31. PubMed ID: 25310898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention).
    Toso A; Leoncini M; Maioli M; Tropeano F; Di Vincenzo E; Villani S; Bellandi F
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1421-9. PubMed ID: 25523533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The Saturn study].
    Fineschi M; Gaspardone A
    G Ital Cardiol (Rome); 2012; 13(7-8):469-73. PubMed ID: 22781373
    [No Abstract]   [Full Text] [Related]  

  • 6. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome).
    Leoncini M; Toso A; Maioli M; Tropeano F; Villani S; Bellandi F
    J Am Coll Cardiol; 2014 Jan 7-14; 63(1):71-9. PubMed ID: 24076283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects and mechanisms of high loading dose rosuvastatin therapy before percutaneous coronary intervention in patients with acute coronary syndrome.
    Luo J; Li J; Shen X; Hu X; Fang Z; Lv X; Zhou S
    Int J Cardiol; 2013 Sep; 167(5):2350-3. PubMed ID: 23194788
    [No Abstract]   [Full Text] [Related]  

  • 8. Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
    Kumar A; Cannon CP
    J Interv Cardiol; 2007 Dec; 20(6):447-57. PubMed ID: 18042049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current statin usage for patients with acute coronary syndrome undergoing percutaneous coronary intervention: multicenter survey in Korea.
    Kim MJ; Jeon DS; Gwon HC; Kim SJ; Chang K; Kim HS; Tahk SJ;
    Clin Cardiol; 2012 Nov; 35(11):700-6. PubMed ID: 22825844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial).
    Kaya A; Kurt M; Tanboğa IH; Işik T; Ekinci M; Aksakal E; Kaya Y; Topçu S; Sevimli S
    Acta Cardiol; 2013 Oct; 68(5):489-94. PubMed ID: 24283110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial.
    Sardella G; Lucisano L; Mancone M; Conti G; Calcagno S; Stio RE; Pennacchi M; Biondi-Zoccai G; Canali E; Fedele F
    Int J Cardiol; 2013 Oct; 168(4):3715-20. PubMed ID: 23849964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study.
    Lablanche JM; Leone A; Merkely B; Morais J; Alonso J; Santini M; Eha J; Demil N; Licour M; Tardif JC;
    Arch Cardiovasc Dis; 2010 Mar; 103(3):160-9. PubMed ID: 20417447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design.
    Lablanche JM; Danchin N; Farnier M; Tedgui A; Vicaut E; Alonso J; Crean P; Leone A; Morais J; Santini M; Licour M; Farah M; Tardif JC
    Arch Cardiovasc Dis; 2008 Jun; 101(6):399-406. PubMed ID: 18809153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The PRATO-ACS study].
    Marenzi G; Briguori C
    G Ital Cardiol (Rome); 2013 Dec; 14(12):803-8. PubMed ID: 24336595
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study).
    Pitt B; Loscalzo J; Monyak J; Miller E; Raichlen J
    Am J Cardiol; 2012 May; 109(9):1239-46. PubMed ID: 22360820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention.
    Liu Y; Liu YH; Tan N; Chen JY; Zhou YL; Li LW; Duan CY; Chen PY; Luo JF; Li HL; Wei-Guo
    PLoS One; 2014; 9(10):e111124. PubMed ID: 25357250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First head-to-head study comparing rosuvastatin and atorvastatin effects on the treatment of atherosclerosis.
    Cardiovasc J Afr; 2008; 19(1):60. PubMed ID: 18320096
    [No Abstract]   [Full Text] [Related]  

  • 18. Statin wars: emphasis on potency vs event reduction and safety?
    Lavie CJ; Milani RV; O'Keefe JH
    Mayo Clin Proc; 2007 May; 82(5):539-42. PubMed ID: 17493417
    [No Abstract]   [Full Text] [Related]  

  • 19. Temporal trends in the use of high-dose potent statins following acute coronary syndrome in Israel.
    Elis A; Pereg D; Dicker D; Gevrielov-Yusim N; Goldenberg I; Matetzky S; Kopel E; Klempfner R
    Cardiology; 2014; 128(3):266-72. PubMed ID: 24863615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High coronary plaque load: a heavy burden.
    de Graaf MA; Jukema JW
    Eur Heart J; 2013 Nov; 34(41):3168-70. PubMed ID: 23966308
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.